Servier: patent settlements were not by-object restrictions

A lawyer for pharmaceutical company Servier said the EU’s antitrust watchdog incorrectly found that agreements delaying the entry of generic rivals to its cardiovascular drug perindopril were by-object restrictions.

Get unlimited access to all Global Competition Review content